Company: GRCE
Filing Date: 2025-07-28
Form Type: DEF 14A
Source: 0001140361-25-027456
Chunk: 47

Company: Grace Therapeutics, Inc.
Filing Date: 2025-07-28
Form: DEF 14A
Chunk 47
---
 Issued Upon Exercise of 
       Outstanding Options, 
    Warrants and Rights (a) |     |        Weighted-Average 
       Exercise Price of 
    Outstanding Options, 
 Warrants and Rights (b) |     |     Number of Securities Remaining 
      Available for Future Issuance 
    Under Equity Compensation Plans 
 (excluding securities reflected in 
                    column (a)) (c) |
| Equity compensation plans approved by security holders     |     |                            |     |                         |     |                                    |
| Grace Therapeutics, Inc. 2024 Equity Incentive Plan        |     |                  15,000(1) |     |                   $3.19 |     |                          1,335,000 |
| Acasti Pharma Inc. Stock Option Plan                       |     |                 919,923(2) |     |                   $3.53 |     |                                  — |
| Acasti Pharma Inc. Equity Incentive Plan                   |     |                       —(3) |     |                       — |     |                                  — |
| Equity compensation plans not approved by security holders |     |                          — |     |                       — |     |                                  — |
| Total                                                      |     |                    934,923 |     |                   $3.52 |     |                          1,335,000 |

| (1) | Consists of outstanding stock options to purchase 15,000 shares of common stock pursuant to the 2024 Plan, which was adopted by our stockholders at 2024 Annual Meeting on September 30, 2024. |

| (2) | Consists of outstanding stock options to purchase 919,923 shares of common stock pursuant to the Acasti Pharma Inc. Stock Option Plan. Following the adoption of the 2024 Plan, no awards will be granted under the Acasti Pharma Inc. Stock Option Plan. |

| (3) | Following the adoption of the 2024 Plan, no awards will be granted under the Acasti Pharma Inc. Equity Incentive Plan. |

31

TABLE OF CONTENTS

TRANSACTIONS WITH RELATED PERSONS AND INDEMNIFICATION Related Person Transactions Policy and Procedures In addition to the Company’s Code of Conduct and Ethics, which serves as the primary guide to avoiding circumstances that may create a conflict, or the appearance of a conflict, between the personal interests of related persons and the interests of the Company, the Board has adopted a written policy with respect to the review, approval or dis